These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1657 related articles for article (PubMed ID: 27507876)
21. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482 [TBL] [Abstract][Full Text] [Related]
22. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Kelly RJ; Shepherd FA; Krivoshik A; Jie F; Horn L Ann Oncol; 2019 Jul; 30(7):1127-1133. PubMed ID: 31070709 [TBL] [Abstract][Full Text] [Related]
23. Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation. An C; Zhang J; Chu H; Gu C; Xiao F; Zhu F; Lu R; Shi H; Zhang H; Yi X Pathol Oncol Res; 2016 Oct; 22(4):763-8. PubMed ID: 27126186 [TBL] [Abstract][Full Text] [Related]
24. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710 [TBL] [Abstract][Full Text] [Related]
25. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993 [TBL] [Abstract][Full Text] [Related]
26. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
27. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lu S; Ye M; Ding L; Tan F; Fu J; Wu B Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283 [TBL] [Abstract][Full Text] [Related]
29. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406 [TBL] [Abstract][Full Text] [Related]
30. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. Wang BC; Zhang WX; Kuang BH; Lin GH PLoS One; 2022; 17(10):e0275919. PubMed ID: 36215289 [TBL] [Abstract][Full Text] [Related]
31. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer. Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888 [TBL] [Abstract][Full Text] [Related]
32. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ Trials; 2015 Apr; 16():146. PubMed ID: 25873045 [TBL] [Abstract][Full Text] [Related]
33. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. Hou X; Li M; Wu G; Feng W; Su J; Jiang H; Jiang G; Chen J; Zhang B; You Z; Liu Q; Chen L JAMA Netw Open; 2023 Feb; 6(2):e2255050. PubMed ID: 36753281 [TBL] [Abstract][Full Text] [Related]
34. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379 [TBL] [Abstract][Full Text] [Related]
35. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). Zhao H; Yao W; Min X; Gu K; Yu G; Zhang Z; Cui J; Miao L; Zhang L; Yuan X; Fang Y; Fu X; Hu C; Zhu X; Fan Y; Yu Q; Wu G; Jiang O; Du X; Liu J; Gu W; Hou Z; Wang Q; Zheng R; Zhou X; Zhang L J Thorac Oncol; 2021 Sep; 16(9):1533-1546. PubMed ID: 34033974 [TBL] [Abstract][Full Text] [Related]
36. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Kim YS; Cho EK; Woo HS; Hong J; Ahn HK; Park I; Sym SJ; Kyung SY; Kang SM; Park JW; Jeong SH; Park J; Lee JH; Shin DB Cancer Res Treat; 2016 Jan; 48(1):80-7. PubMed ID: 25761488 [TBL] [Abstract][Full Text] [Related]
37. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Kato T; Yoshioka H; Okamoto I; Yokoyama A; Hida T; Seto T; Kiura K; Massey D; Seki Y; Yamamoto N Cancer Sci; 2015 Sep; 106(9):1202-11. PubMed ID: 26094656 [TBL] [Abstract][Full Text] [Related]
38. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853 [TBL] [Abstract][Full Text] [Related]
39. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T; Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]